Discover a publicly traded biotech company advancing treatment options for critical diseases.

60 Degrees Pharma is a biotech company focused on addressing unmet medical needs. We are proud to advance treatments for serious health challenges, including solutions for tick-borne babesiosis. As a publicly traded company, SXTP is committed to transparency, innovation, and driving value for stakeholders.

SXTP

SXTP

SXTP

SXTP

Disclaimer: Growth Cap Report does not provide financial advice. All investment decisions should be made in consultation with a licensed financial advisor. We respect your privacy and comply with data protection laws. View our full Privacy Policy

FDA Disclaimer: Any references to products are not endorsements and should not be construed as medical advice

Emerging Threat: Tick-borne diseases, particularly babesiosis, are becoming a public health crisis, creating a rapidly growing market need.

Strategic Growth: Expand commercial potential for both malaria and tick-borne disease treatments. Ongoing collaborations, including with the U.S. Army.

Seeking new indication from already approved preventative malaria treatment. Arakoda® is now being evaluated for babesiosis through clinical trials at Yale, Rhode Island Hospital, and Tufts Medical Center.

SXTP

SXTP

SXTP

SXTP

Disclaimer: Growth Cap Report does not provide financial advice. All investment decisions should be made in consultation with a licensed financial advisor. We respect your privacy and comply with data protection laws. View our full Privacy Policy

Developing and commercializing new products that address the unmet medical needs associated with infectious diseases.

Founded in 2010, 60 Degrees Pharmaceuticals is dedicated to developing innovative treatments for infectious diseases, focusing on tick-borne illnesses and tropical diseases. Initially targeting dengue, the company has expanded to address major unmet needs in the infectious disease landscape. The company’s lead product, Arakoda, is being repurposed to treat tick-borne babesiosis, an emerging health threat often referred to as "American malaria."

Babesiosis Treatment Potential: Supported by human and animal research, Arakoda is being evaluated as a potential treatment for acute and chronic babesiosis, conditions with serious health consequences.

Clinical Trials: 60 Degrees Pharmaceuticals is conducting trials at Yale University, Rhode Island Hospital, and Tufts Medical Center to assess Arakoda’s effectiveness against babesiosis.

Growing Need: The CDC reports increasing cases of babesiosis, underlining a critical gap in treatment options—one that 60 Degrees Pharmaceuticals aims to address.

Tick-borne diseases are emerging as a public health crisis, with babesiosis alone potentially affecting up to 1 million Americans. As one of the few public companies actively developing treatments for these conditions, 60 Degrees Pharmaceuticals is well-positioned to provide critical solutions.

With a market cap of only $3-4 million, 60 Degrees Pharmaceuticals represents a rare investment opportunity in the biotech sector. By seeking to expand the market for its FDA-approved product, the company has multiple avenues for growth:

Tick-borne Disease Market: The rising incidence of tick-borne diseases provides significant growth potential.

Malaria Prevention: The company continues to generate sales for malaria prevention while expanding into new markets.

Strategic Partnerships: Collaborations, such as with the U.S. Army, enhance Arakoda’s commercial potential.

Risk Disclosure Statement

This corporate profile has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in this corporate profile. Individuals should assume that all information in this corporate profile is not trustworthy unless verified by their own independent research.

The profiled company has not reviewed or approved the content herein. This paid advertisement has been compiled from publicly available information, which includes, but is not limited to, independent online research, magazines, newspapers, reports filed with the SEC or information furnished to OTC Markets, and press releases from the company profiled. Any information contained in this paid information does not represent opinions, forecasts or predictions by the company or its management. 

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

Information contained in this corporate profile will contain “forward-looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.

This report is a paid advertisement. The company profiled herein is a investor relations client of Ludlow Business Services, Inc. Ludlow has received $10,000 as compensation from the company profiled herein for preparation, publication, management, and advertising of this company profile (as required by Section 17(b) of the Securities Act.) Ludlow Business Services, LLC, and its principals currently hold 3,125 shares in the company profiled above and may purchase or sell such shares at any time without notice. Our receipt of compensation and services to the profiled company constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.

This paid advertisement is not a solicitation or recommendation to buy or sell securities of the profiled company. Such recommendations may only be made pursuant to applicable laws. This paid advertisement is not a disclosure document. If you are considering purchasing any securities of the profiled company, you should read and review, if and to the extent available, any information concerning the profiled company available at the websites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov ; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org and the state securities regulators. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. You are responsible for verifying all claims and conducting your due diligence.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. 

Statistical information, dollar amounts, and market size data were sourced from publicly disclosed corporate material and filings which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this profile, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of the information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

Disclaimer | Privacy Policy | About Us | Contact Us | Terms and Conditions | FAQ

Owned and operated by Ludlow Business Services, Inc |  © 2025 All Rights Reserved

Contact us:                                                                                                                                                                                                                                                           270 Bellevue Ave #1111

[email protected]                                                                                                                                                                                                                                 Newport, RI 02840-3516                                                                                                                                                                                                                                                                                                 United States